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Abstract
Introduction. Many anti-tumor drugs have a high potential for toxic damage to liver cells, which makes it necessary to 
identify molecular mechanisms of the development of the negative impact of drugs on the liver and to develop effective 
methods for preventing and correcting this adverse effect. 
Materials and methods. The study was performed on 30 nonlinear white rats of both sexes weighing 180–220 g, di-
vided into 3 equal groups (n = 10 in each): intact control, control with liver pathology and experimental group of rats 
receiving the test substance LBK-527 at a dose of 100 mg/kg/day intragastrically one hour before the administration 
of a hepatoxic cytarabine. In the animals of the latter two groups, acute drug-induced hepatitis was simulated by intra-
venous administration of 2 g/m2 cytarabine in physiological saline for 5 days. Liver pathomorphology was studied on 
specimens stained with hematoxylin and eosin, Sudan III and by Van Gieson; a semi-quantitative method for assessing 
the depth of inflammatory and dystrophic organ damage was used. In the blood plasma, the activity of ASAT, ALAT, 
GGTP, and APF was determined. Tissue concentrations of TNF-alpha, IL-10 and HGF were determined by quantitative 
ELISA. Expression of Bcl-2 and Ki-67 was studied by immunohistochemistry. The proliferation index was calculated. 
Results and discussion. Daily administration of LBK-527 for 5 days restrains the depth of cytarabine-induced patho-
morphological changes in the liver, reduces the prevalence of the dystrophic and inflammatory process, increases the 
anti-inflammatory and regenerative potential of the hepatic parenchyma, inhibits the programmed death of hepatocytes 
and reduces the activity of cytolytic and cholestatic syndromes.
Conclusion. Magnesium-containing cell-protective substance LBK-527 protects liver from cytarabine-induced injury.
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Introduction
Diagnosis of drug damage to the liver is often difficult 
due to the fact that the hepatotoxic effect of many drugs 
can mimic other organ diseases (Bénichou 1990). In ad-
dition, there are neither specific biological – histological 
or biochemical – markers of drug-induced hepatotoxicity, 
nor are there reliable methods for identifying a hepato-
toxicant in the vast majority of cases (Mori et al. 1997, 
Remesh 2012). In the case of antitumor chemotherapy, 
the situation is complicated by the severity of the under-
lying disease, which under certain circumstances can also 
cause impairment of the function and morphology of the 
liver (Larroquette et al. 1986). Against the background 
of the administration of specific anti-tumor agents, slight 
hyperenzymemia is generally ignored by clinicians, whe-
reas the leading principles at the appearance of signs of 
hepatotoxic effect of drugs are early diagnosis and imme-
diate discontinuation of the drug in the body (Farrow et al. 
1997, Twelves et al. 1998).
At the same time, most anti-tumor drugs have a high 
potential for damage to liver structures: hepatocytes, en-
dothelial cells of sinusoids, and macrophage elements 
colonizing the organ (DeLeve 1996). All this makes it 
necessary to identify molecular mechanisms for the deve-
lopment of the negative impact of drugs on the liver and 
to develop effective methods for preventing and correc-
ting this adverse effect.
Study goal
To validate the points of application of the hepatoprotec-
tive effect of the magnesium-containing 2-aminoethane-
sulfonic acid derivative, based on the analysis of the key 
molecular and cellular processes underlying the develop-
ment of acute drug damage to the rat liver with an anti-tu-
mor drug cytarabine.
Materials and methods 
Experimental animals
The experiments were performed on 30 white nonlinear 
rats of both sexes with a baseline weight of 180–220 g, 
obtained from Andreevka Branch of the Scientific Center 
for Biological and Medical Technologies, in compliance 
with the requirements of order No. 199н of the Ministry 
of Healthcare of Russia dated 01.04.2016 “On Approval 
of the Rules of Good Laboratory Practice”, based on the 
principles of humane treatment of experimental animals 
in accordance with the European Convention for the Pro-
tection of Vertebrates. The protocols of the experiments 
passed an ethical review at a meeting of the Local Eth-
ics Committee of Ogarev National Research Mordovia 
State University (October 21, 2017, Minutes No. 10). 
The animals were divided into 3 experimental groups 
of 5 females and 5 males in each: 1st  – intact animals; 
2nd – control with cytarabine-induced acute drug damage 
(CIADD); 3rd – animals with CIADD treated with the test-
ed substance (LBK-527).
CIADD modeling method
Acute drug damage to the liver was formed by intraven-
ous administration of cytarabine at a dose of 2 g/m2 of 
the animal’s body surface in 3 ml physiological saline 
to the rats of the 2nd and 3rd groups for 5 days (Singh 
et al. 2012, Liu et al. 2013, Lakshmi et al. 2014). Cy-
tosar 100 mg, lyophilizate for solution for intravenous 
injections (manufactured by Pfizer Inc., Germany), was 
used. The same amount of physiological saline was ad-
ministered intravenously to the intact rats daily. On the 
sixth day, the rats were sacrificed by decapitation under 
ether anesthesia.
Biochemistry
The activity of aspartate aminotransferase (ASAT), ala-
nine aminotransferase (ALAT), gamma-glutamyl trans-
peptidase (GGTP), alkaline phosphatase (APF) was de-
termined in the blood serum using a FUJI DRI CHEM 
4000i veterinary biochemical analyzer (Japan) and using 
a FUJIFILM standard diagnostic kit (Japan).
Morphological examination
The liver was removed from the animals, and after being 
weighed and visually examined, it was divided into four 
approximately equal parts. One organ fragment was fixed 
in 10% neutral formalin solution; after being drained, it 
was embedded into paraffin and used for histological exa-
mination after having the sections stained with hematoxy-
lin and eosin, and special Van-Gieson staining. To do this, 
after deparaffinisation, using a sledge microtome, 5–6 μm 
thick slices were made and stained with dyes by standard 
techniques. The second, non-fixed, fragment of the liver 
was frozen and then stained with an alkaline solution of 
Sudan III. Morphometry of the liver sections was analy-
zed using the Image Scope Color and cellSens Standard 
image analysis software (Russia). For this purpose, pho-
tomicrographs of random visual fields of histological 
preparations were taken by OLYMPUS XCOLYMPUS 
XC-30 digital camera based on OLYMPUS BX51 micro-
scope (Japan) with eyepiece magnification SWHx10 and 
UPLanFL x200, x400 lenses (at least 10 fields of vision 
in each histological section). On haematoxylin and eosin 
sections, a semi-quantitative analysis of the CIADD seve-
rity was used in terms of the area of hepatic parenchyma 
affected by the inflammatory-dystrophic process (Zhao 
et al. 2017). Using specimens stained with Sudan III, the 
percentage of hepatocytes with steatosis phenomena was 
determined, as well as the area of hepatocyte cytoplasm 
covered with fat drops.
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Immunohistochemistry
The third fragment of the liver was frozen, then 3–4 
μm thick cryostat sections were used for immunohisto-
chemistry (IHC) with streptavidin-biotin amplification 
method. Rabbit Polyclonal IgG Bcl-2 Antibodies (C21) 
(Santa Cruz, USA) were applied to apoptosis regulator 
Bcl-2, and Mouse Monoclonal Anti-Ki-67 ((Clone MM1) 
(K-2), IgG1, Novo Castra, United Kingdom) – to Ki-67 
proliferation factor. Mayer’s hematoxylin was used for 
the contrast staining of the nuclei. Analysis of the IHC 
reaction was carried out in 6 fields of vision (3 fields from 
the central lobular and 3 ones from the peripheral parts of 
the hepatic lobule), with ×400 magnification. A proporti-
on of Bcl-2-positive cells was determined; the proliferati-
on index was calculated to evaluate the response to Ki-67.
ELISA test
TNF-alpha, hepatocyte growth factor (HGF), and IL-10 
concentration in liver tissue was determined in the homo-
genate of the fourth liver fragment by means of quanti-
tative ELISA and a research kit of antibodies (Cusabio 
Biotech Co., LTD., USA) on a StatFax 4200 automatic 
reader (USA).
Studied pharmacological agent
The magnesium salt of 2-aminoethanesulfonic acid (the 
code of the developer’s institution – LBK-527) was stu-
died as a substance (All-Union Research Center for Bio-
logical Active Substances Safety, Russia). The tested 
substance was daily administered to the animals intragas-
trically, 1 hour prior to the administration of cytarabine at 
a dose of 100 mg/kg/day for 5 days. The intact animals 
and the rats with CIADD (groups 1 and 2) from the con-
trol group were administered drinking water in a similar 
regime and amount throughout the experiment.
Statistical data processing
The data were statistically processed by parametric and 
nonparametric methods, with a 5% level of significance 
by means of the BioStat software (Glantz 2012).
Results and discussion
Daily intravenous administration of 2 g/m2 of the animal’s 
body surface area of cytarabine in rats for 5 days morpho-
logically manifested by an increase in absolute and re-
lative liver mass and hepatocyte hypertrophy, structural 
damage of the organ, vacuolization of the cytoplasm of 
hepatocytes, karyopicnosis and karyolysis, the appea-
rance of necrosis, leuco- and lymphohistiocytic infiltra-
tion, steatosis and the initial signs of fibrosis. The use of 
a semi-quantitative method for assessing the prevalence 
of the inflammatory-dystrophic process made it possible 
to assess the depth of the organ pathological changes, 
characterized by involving more than 66% of the liver pa-
renchyma into the pathological process (Table 1).
Intragastric administration of magnesium-containing 
compound of 2-aminoethanesulfonic acid at a dose of 100 
mg/kg/day to rats receiving cytarabine inhibited the for-
mation of a pattern of acute toxic liver damage, which 
manifested itself in normalizing the structural organizati-
Table 1. Semi-quantitative Characteristics of Inflammatory-dys-
trophic Liver Reaction of Rats with CIADD under the Influence 
of LBK-527 According to Zhao et al. 2017.
Group of animals 0 + ++ +++
Intact rats 10 0 0 0
Control with CIADD 0* 0 3 7*
CIADD, LBK-527 100 mg/kg/day 0* 7А* 3 0А
Note: * – р<0,05 in comparison with intact rats; А – р<0,05 in compari-
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Figure 1. Morphometric features of fatty dystrophy of rats with CIADD treated with LBK-527. Note: # – р<0,05 in comparison with 
intact rats; * – р<0,05 in comparison with intact rats and control with CIADD (ANOVA, Dannet criterion)
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on of the hepatic parenchyma, reducing the depth of the 
inflammatory and dystrophic process (Table 1), and ab-
sence of signs of expansion of connective tissue elements.
The severity of steatosis, quantitatively characterized 
by the proportion of hepatocytes with fatty dystrophy and 
the area of cytoplasm of the liver parenchyma cells under 
fatty drops significantly decreased when compared to tho-
se in the animals in the control group (Figure 1).
The result of the histoprotective effect of LBK-527 
compound was a decrease in the plasma concentration of 
intracellular enzymes (ASAT, ALAT and GGTP) when 
compared to that in the animals of the control with CIADD, 
and a decrease in the intrahepatic cholestasis (Table 2).
Five days after the course of daily intravenous injec-
tion of cytarabine solution to the animals, an increase in 
TNF-alpha tissue concentration by more than two and a half 
times – on average to 26.2 pg/ml (p = 0.001 when compared 
to the intact animals) against the background of almost a 
four-fold decrease in the level of anti-inflammatory cyto-
kine-IL-10 to 3.8 pg/ml (p = 0.001 when compared with 
intact animals) – was observed. At the same time, a propor-
tional (four-fold) increase in tissue concentration of hepa-
tocyte growth factor (HGF) – up to 0.61 pg/ml (p = 0.001 
when compared to the intact animals) was observed, which 
was regarded as a compensatory reaction aimed to form hy-
pertrophy of hepatocytes and their functional replacement 
in response to cytarabine-induced death of hepatocytes.
LBK-527 at a dose of 100 mg/kg/day also had a sig-
nificant effect on tissue concentrations of cytokines in 
the liver of animals with emerging acute drug hepatitis 
(Table 2). Tissue concentration of pro-inflammatory cyto-
kine TNF-alpha was restored to reach the values obser-
ved in the liver of intact animals; the level of IL-10 was 
50% higher than that in the intact group. The tissue level 
of HGF against the background of administration of the 
compound remained high.
In the intact animals, a low expression of the apoptosis 
regulatory factor was observed, as judged from the low 
intensity of brown staining of the hepatocyte cytoplasm 
(Fig. 2a). Against the background of the formation of 
acute cytarabine-induced damage to the hepatic parenc-
hyma, an increased expression of Bcl-2 in the animals’ 
liver microscopic specimens was observed (Fig. 2b), 
which may indicate a compensatory activation of tissue 
protective mechanisms against the background of emer-
ging necrosis and an inflammatory response: a moderate 
immunohistochemical reaction was registered predomi-
nantly in hepatocytes of the central parts of the lobule. 
The antiapoptotic effect of LBK-527 at a dose of 100 mg/
kg/day was evident by highly intensive staining of the 
cytoplasm of hepatocytes, mainly in the central part of 
the liver lobule (Fig. 2C, D). 
Ki-67 is a highly sensitive marker of cell proliferation 
(Pujani et al. 2011). The liver parenchyma of intact rats is 
Table 2. The Values of Some Biochemical Parameters of Liver Function and Tissue Concentration of Cytokines (M±SD) in Rats 
with CIADD Treated with LBK-527.
Group ASAT АLAТ APF GGTP FNO-alpha IL-10 HGF
U/l U/l U/l U/l pg/ml pg/ml pg/ml
Intact Rats 13.8±2.3 11.3±1.4 219.5±8.5 1.1±0.3 10.6±0.8 13.2±0.6 0.16±0.03
Control with CIADD 281.7±5.2* 69.1±2.2* 293.6±6.1* 7.1±0.7* 26.2±1.6* 3.8±0.4* 0.61±0.09*
CIADD, LBK-527 100 mg/kg/day 119.6±3.1В* 47.2±3.6В* 211.0±3.4В 2.2±0.5В 13.0±1.3В 19.1±1.5В* 0.84±0.11В
Note: * – р<0.05 when compared to intact rats; В – р<0.05 when compared to control with CIADD (ANOVA, Dannet criterion)
Figure 2. IHC study of liver. Bcl-2 staining. ×400: A intact rats; B control with CIADD; rats with CIADD treated with LBK-527, 
100 mg/kg/day; C center of lobule; D the lobule periphery
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Figure 3. Ki-67 expression in rat’s hepatocyte nuclei (indicated by the arrows, x 400): A intact rat’s liver; B liver of rat with CIADD; 
liver of rat with CIADD treated with LBK-527, 100 mg/kg/day C lobule periphery; D center of the lobule.
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expressed by resting non-proliferating hepatocytes (Fig. 
3a). In the liver of the animals with CIADD, expression 
of Ki-67 was observed neither in the centrolobular nor 
in the peripheral parts of the liver lobule (Fig. 3b). The 
pharmacological effect of LBK-527 was accompanied by 
an increase in the expression of the proliferation marker 
(Figure 3c, d), as evidenced by an increase in the prolife-
ration index (Fig. 4).
Thus, intravenous administration of toxic doses of 
cytarabine induces acute drug liver damage in rats char-
acterized by the development of necrosis, the inflamma-
tory-dystrophic reaction, activation of apoptosis of he-
patocytes, hypertrophy of parenchymal cells, cytolysis 
and cholestasis. Prophylactic intragastric administration 
to animals of a magnesium-containing compound of 
2-aminoethanesulfonic acid at a higher therapeutic dose 
of 100 mg/kg daily for 5 days makes it possible to re-
strain the hepatotoxicity of cytarabine and to reduce the 
depth of damage to the liver of animals.
Conclusions 
1. Daily intragastric LBK-527 administration leads to the 
preservation of the microstructure of the liver: the lo-
bular morphology and the beam structure of the organ 
parenchyma, the prevention of hepatic cell death, and a 
decrease in the intensity of the inflammatory-dystrop-
hic process mainly of the lobular center.
2. The liver-protective effect of substance LBK-527 against 
the background of the development of acute cytarabi-
ne-induced liver damage is manifested in the prevention 
of anticancer drug-mediated cytolysis and cholestasis.
3. LBK-527 reduces the tissue concentration of TNF-alpha, 
restores the level of anti-inflammatory IL-10 to the level 
of that in the intact animals, increases the expression of 
the anti-apoptotic factor Bcl-2 and activates the prolife-
ration potential of hepatocytes (Ki-67 level), mainly in 
the periphery of the hepatic lobule in the animals recei-
ving toxic doses of antitumor anti-metabolite cytarabine.
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